Thorax perfusion CT in non-small cell lung cancer

Ovalı, Gülgün Yılmaz; Şakar, Ayşın; Göktan, Cihan; Çeli̇k, Pınar; Yorgancıoğlu, Arzu; Neşe, Nalan; Pabuşçu, Yüksel

doi:10.1016/j.compmedimag.2007.08.005

Cited by 13 publications

(6 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Tumour cavitation, beam-hardening artefacts and small tumour size were the main reasons why perfusion could not be reliably measured. The last two of these factors are known to prohibit perfusion measurements [27, 28]. …”

Section: Discussionmentioning

confidence: 99%

Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?

et al. 2010

View full text Add to dashboard Cite

ObjectiveWe investigated the feasibility of serial dynamic contrast-enhanced computed tomography (DCE-CT) in patients with advanced/metastatic non-small cell lung cancer (NSCLC) receiving anti-angiogenic (sorafenib) and anti-EGFR (erlotinib) treatment, and correlated tumour blood flow (BF) with treatment outcome.MethodsDCE-CTs were performed at baseline and 3 and 6 weeks after starting treatment. Tumour BF, calculated with the maximum slope method, and percentage change were measured in 23 patients (14 male; median age 59 years). Tumour BF was compared at baseline and weeks 3 and 6; the relation with RECIST/Crabb response and progression-free survival (PFS) was assessed.ResultsMean tumour perfusion decreased from 39.2 ml/100 g/min at baseline to 15.1 ml/100 g/min at week 3 (p < 0.001) and 9.4 ml/100 g/min at week 6 (p < 0.001). Tumour perfusion was lower in RECIST and Crabb responders versus non-responders at week 3 (4.2 versus 17.7 ml/100 g/min, p = 0.03) and week 6 (0 versus 13.4 ml/100 g/min, p = 0.04). Patients with a decrease larger than the median at week 6 tended to have a longer PFS (7.1 versus 5.7 months, p = 0.06).ConclusionSerial DCE-CTs are feasible in patients with NSCLC and demonstrated a significant decrease in tumour BF following sorafenib/erlotinib therapy. Early changes in tumour BF correlated with objective response and showed a trend towards longer PFS.

show abstract

Section: Discussionmentioning

confidence: 99%

Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?

et al. 2010

View full text Add to dashboard Cite

show abstract

“…18F-deoxyglucose positron emission tomography can provide more information about the functional metabolism of the lesion, but its use in clinical practice is limited due to its high cost and excessive radiation dose (5,6). In recent years, with the rapid development of CT functional imaging, spectral and perfusion CT imaging have shown advantages in the diagnosis and differentiation of lung tumors (7)(8)(9). Spectral CT imaging can provide a variety of imaging parameters, such as single-energy image, spectral curve, effective atomic number (Zeff), and basic material image, which has potential value in the qualitative analysis of lesions and determination of tumor grade and origin (10,11).…”

Section: Introductionmentioning

confidence: 99%

Comparison of Spectral and Perfusion Computed Tomography Imaging in the Differential Diagnosis of Peripheral Lung Cancer and Focal Organizing Pneumonia

et al. 2021

View full text Add to dashboard Cite

ObjectiveTo investigate the spectral and perfusion computed tomography (CT) findings of peripheral lung cancer (PLC) and focal organizing pneumonia (FOP) and to compare the accuracy of spectral and perfusion CT imaging in distinguishing PLC from FOP.Materials and MethodsPatients who were suspected of having lung tumor and underwent “one-stop” chest spectral and perfusion CT, with their diagnosis confirmed pathologically, were prospectively enrolled from September 2020 to March 2021. Patients who were suspected of having lung tumor and underwent “one-stop” chest spectral and perfusion CT, with their diagnosis confirmed pathologically, were prospectively enrolled from September 2020 to March 2021. A total of 57 and 35 patients with PLC and FOP were included, respectively. Spectral parameters (CT40keV, CT70keV, CT100keV, iodine concentration [IC], water concentration [WC], and effective atomic number [Zeff]) of the lesions in the arterial and venous phases were measured in both groups. The slope of the spectral curve (K70keV) was calculated. The perfusion parameters, including blood volume (BV), blood flow (BF), mean transit time (MTT), and permeability surface (PS), were measured simultaneously in both groups. The differences in the spectral and perfusion parameters between the groups were examined. Receiver operating characteristic (ROC) curves were generated to calculate and compare the area under the curve (AUC), sensitivity, specificity, and accuracy of both sets of parameters in both groups.ResultsThe patients’ demographic and clinical characteristics were similar in both groups (P > 0.05). In the arterial and venous phases, the values of spectral parameters (CT40keV, CT70keV, spectral curve K70keV, IC, and Zeff) were greater in the FOP group than in the PLC group (P < 0.05). In contrast, the values of the perfusion parameters (BV, BF, MTT, and PS) were smaller in the FOP group than in the PLC group (P < 0.05). The AUC of the combination of the spectral parameters was larger than that of the perfusion parameters. For the former imaging method, the AUC, sensitivity, and specificity were 0.89 (95% confidence interval [CI]: 0.82–0.96), 0.86, and 0.83, respectively. For the latter imaging method, the AUC, sensitivity, and specificity were 0.80 (95% CI: 0.70–0.90), 0.71, and 0.83, respectively. There was no significant difference in AUC between the two imaging methods (P > 0.05).ConclusionSpectral and perfusion CT both has the capability to differentiate PLC and FOP. However, compared to perfusion CT imaging, spectral CT imaging has higher diagnostic efficiency in distinguishing them.

show abstract

“…Perfusion CT is already performed in the patient's routine CT examination via software, conferring a worthwhile enhancement to the conventional CT with additional functional evaluations. The major clinical applications of perfusion CT are acute stroke, cancer, and myocardial infarction [3,16,17]. Currently, perfusion CT has very limited application in urology such as kidney dynamic imaging in the assessments of glomerular filtration; it has also been used to demonstrate reduced renal perfusion in hypertension and abdominal aortic aneurysm, renal artery stenosis, chronic renal obstruction, and cyclosporin toxicity [3,7,[11][12][13][14]18].…”

Section: Discussionmentioning

confidence: 99%

Perfusion computed tomography could be a new tool for single-session imaging of ureteric obstructive pathology: an experimental study in rats

Yılmaz

Ovalı

Genç

et al. 2009

Journal of Pediatric Surgery

View full text Add to dashboard Cite

Thorax perfusion CT in non-small cell lung cancer

Cited by 13 publications

References 11 publications

Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?

Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?

Comparison of Spectral and Perfusion Computed Tomography Imaging in the Differential Diagnosis of Peripheral Lung Cancer and Focal Organizing Pneumonia

Perfusion computed tomography could be a new tool for single-session imaging of ureteric obstructive pathology: an experimental study in rats

Contact Info

Product

Resources

About